Press Releases

BioCryst Pharmaceuticals, Inc. announced that Mundipharma has obtained regulatory approval of Mundesine® (Forodesine hydrochloride) for the treatment of relapsed/refractory PTCL…
Read More...

Eisai Co., Ltd. and Meiji Seika Pharma Co., Ltd. announced that they have entered into a license agreement for the commercialization of safinamide (development code: ME2125) for the…
Read More...

uniQure announced the online publication in Gene Therapy of data demonstrating widespread transduction in the CNS following direct injection of uniQure's AAV5 vector in a large animal…
Read More...

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products announced that it…
Read More...

Puma Biotechnology, Inc., a biopharmaceutical company, has initiated an expanded access program (EAP) in the United States to provide its investigational therapy, PB272 (neratinib), to…
Read More...

Sharp Packaging Services (“Sharp”), a division of UDG Healthcare, plc, a global leader in contract packaging and clinical supply services, today announced that it has acquired a…
Read More...

Sharp Clinical Services (Sharp), part of UDG Healthcare plc has announced a £9 million  investment to fund a new multiple-phase pharmaceutical manufacturing, packaging and distribution…
Read More...

Astellas Pharma Inc. and Ogeda SA announced that Astellas and Ogeda shareholders have entered into a definitive agreement under which Astellas has agreed to acquire Ogeda a privately…
Read More...

A U.S. patent board on Friday ruled against Danish drugmaker Forward Pharma A/S, finding Biogen's patents on its blockbuster multiple sclerosis drug Tecfidera to be valid. The ruling…
Read More...

miRagen Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today announced that the U.S. Food and…
Read More...

Espero Pharmaceuticals, Inc., a privately held, commercial-stage cardiovascular pharmaceutical company, and Armetheon, Inc., a privately held, late-clinical stage pharmaceutical company…
Read More...

Hilleman Laboratories, a joint-venture partnership between MSD and Wellcome Trust, signed a Memorandum of Understanding (MoU) with National Institute of Cholera and Enteric Diseases…
Read More...

Clinical-stage immuno-oncology firm Agenus is reorganizing its business and operations to straighten its focus on clinical development of its two checkpoint inhibitor antibodies and…
Read More...

Vanda Pharmaceuticals Inc. announced that it has entered into a license agreement with UC San Francisco (UCSF), under which Vanda will acquire an exclusive worldwide license from UCSF…
Read More...

Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced…
Read More...

Mylan N.V., today announced the successful acquisition of the global rights to the Cold-EEZE brand cold remedy line from ProPhase Labs, Inc. The transaction provides Mylan all assets…
Read More...

Mylan announced the successful acquisition of the global rights to the Cold-EEZE brand cold remedy line from ProPhase Labs, Inc. The transaction provides Mylan all assets and rights…
Read More...

Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced…
Read More...

Mylan N.V., today announced the successful acquisition of the global rights to the Cold-EEZE brand cold remedy line from ProPhase Labs, Inc. The transaction provides Mylan all assets…
Read More...

Vanda Pharmaceuticals Inc. announced that it has entered into a license agreement with UC San Francisco (UCSF), under which Vanda will acquire an exclusive worldwide license from UCSF…
Read More...